TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6387529
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg single dose and 240 mg/day for 2 weeks)
Study: 26273143
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose captopril (Cap1hr) before surgery with Iso (Cap1hr+Iso)
Study: 26273143
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of captopril and Iso (Iso+Cap) in rabbits
Study: 24151017
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate (starting dose 800 mg three times daily)
Study: 15037936
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction with routine antibiotic and anti‐inflammatory treatment
Study: 15037936
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic and anti‐inflammatory treatment alone (control)
Study: 11779396
Drug: Cold-adapted, live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine (CAIV-T)
Study: 7942878
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with morphine sulfate 1 mg or meperidine hydrochloride 10 mg, six-minute lockout period
Study: 7942878
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) analgesic therapy with meperidine hydrochloride 75-100 mg every three to four hours as needed
Study: 3392233
Drug: Nilvadipine 2
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 2 mg
Study: 3392233
Drug: Nilvadipine 6
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 6 mg
Study: 3392233
Drug: Nilvadipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (all doses)
Study: 31008870
Drug: 0.05 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 μg/kg/min norepinephrine
Study: 31008870
Drug: 0.5 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg/min phenylephrine
Study: 26980809
Drug: Subcutaneous 300
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous 300 µg GCSF before implantation
Study: 19112802
Drug: 2% mequinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mequinol (4‐hydroxyanisole, 4HA) and 0.01% tretinoin (Solagé) applied twice daily for 3 months
Study: 8415169
Drug: Glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer cement with daily application of sodium fluoride gel (pH 5.8)
Study: 8415169
Drug: Glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer cement without topical fluoride
Study: 3535055
Drug: Oral norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral norfloxacin (400 mg every 12 hours)
Study: 29367449
Drug: Zonisamide 50
Normalized name: zonisamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 50 mg once daily
Study: 17348239
Drug: Concurrent rhinoconjunctivitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent rhinoconjunctivitis
Study: 17348239
Drug: Concurrent chronic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent chronic flexural rash
Study: 8865706
Drug: 3 l.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 l. min(‐1) oxygen with face mask for the initial 3 hours
Study: 8865706
Drug: 3 l.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 l. min(‐1) oxygen inhalation through the face mask
Study: 6435655
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (5 mg i.v.)
Study: 31259655
Drug: FPS 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPS 100/50 μg once daily (QD)
Study: 31259655
Drug: FPS 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPS 100/50 μg twice daily (BID)
Study: 31259655
Drug: FPS 250/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPS 250/50 μg BID
Study: 31259655
Drug: FPS 500/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPS 500/50 μg BID
Study: 26977121
Drug: Standardised Fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised Fermented Papaya Gel (SFPG) applied intragingivally (7 g) for 15 minutes daily for 10 days
Study: 26977121
Drug: Standardised Fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised Fermented Papaya Gel (SFPG)
Study: 21186968
Drug: Psychotropic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic treatment history
Study: 16936304
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP) [ethinyl estradiol (E(2)) 30 microg + desogestrel 150 microg]
Study: 16936304
Drug: Norethisterone 10
Normalized name: ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone 10 mg/day
Study: 16936304
Drug: 17-betaE(2) 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-betaE(2) 4 mg/day
Study: 11255520
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 days, followed by full‐dose (10 mg) ramipril until day 90
Study: 11255520
Drug: Low‐dose (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose (0.625 mg) ramipril for 90 days
Study: 11255520
Drug: Full‐dose ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full‐dose ramipril for 90 days
Study: 28801421
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) group receiving 10 sessions of EA treatment over 4 weeks
Study: 28801421
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group not receiving EA treatment
Study: 24122389
Drug: docetaxel/capecitabine (docetaxel:
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel/capecitabine (docetaxel: 75 mg/m2 on day 1; capecitabine: 1,650 mg/m2 on days 1–14 every 3 weeks)
Study: 24122389
Drug: docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel alone (75 mg/m2 on day 1 every 3 weeks)
Study: 24122389
Drug: pre-treatment Ki67LI
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-treatment Ki67LI
Study: 16823593
Drug: Chemotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group treated with mitomycin C, 5‐fluorouracil (5‐FU), and HCFU
Study: 16823593
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no postoperative adjuvant chemotherapy)
Study: 12783913
Drug: 12.5 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/d paroxetine CR
Study: 12783913
Drug: 25.0 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25.0 mg/d paroxetine CR
Study: 1299708
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg isoniazid (INH)
Study: 24951609
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy (capecitabine or fluorouracil, plus cisplatin)
Study: 16358878
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine pranobex (Groprinosin) 50 mg/kg b.w/day for 10 days in 3 following months
Study: 9856371
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (25 mmol/day or 1 g/day of calcium as calcium carbonate)
Study: 2212020
Drug: Peripheral streptomycin/lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral streptomycin/lidocaine injections (S/L)
Study: 38214
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg labetalol
Study: 31549255
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) with inhaled corticosteroids (ICS) alone or in combination with a long-acting β2-agonist (ICS/LABA)
Study: 26130237
Drug: Ubiquinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (200 mg enteral, twice a day for up to seven days)
Study: 26130237
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice a day for up to seven days)
Study: 11281339
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (90 mg/day)
Study: 8201073
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (flooding)
Study: 3295317
Drug: 45% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45% BCAA intravenous solution
Study: 3295317
Drug: 23% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23% BCAA intravenous solution
Study: 28729154
Drug: Tremelimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (10 mg/kg) every 4 weeks for 7 doses and every 12 weeks thereafter until treatment discontinuation
Study: 25987645
Drug: Clonazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (20 patients took 0.5 mg once a day for 2 weeks, then 0.5 mg in the morning and evening for the next 2 weeks)
Study: 23372745
Drug: 3.36 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.36 g/d EPA and DHA
Study: 21515479
Drug: Volume-controlled ventilation
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volume-controlled ventilation (VCV) without positive end-expiratory pressure (PEEP) (VT=8 ml/kg, Rf=12/min)
Study: 21515479
Drug: Small tidal
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small tidal volume ventilation with PEEP (VT=6 ml/kg, Rf=16/min, PEEP=5 cm H(2)O)
Study: 19637348
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (3-drug chemotherapy without ifosfamide)
Study: 11570021
Drug: Sibutramine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (20 mg/d)
Study: 7978471
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 40 mg.kg‐1 infused over 60 min after induction of anesthesia and 4 h later
Study: 2568015
Drug: Antacids in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids in very high doses
Study: 2568015
Drug: Prokinetic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic drugs
Study: 2568015
Drug: Antacids, antacid/alginate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids, antacid/alginate, metoclopramide, domperidone
Study: 24621976
Drug: urocortin-2 infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: urocortin-2 infusion (5 ng/kg/min for 4 hours)
Study: 18340390
Drug: Home Blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Blood Pressure Monitoring (HBPM) with long-acting diltiazem (240 mg/day)
Study: 17154747
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (IBCT and TBCT)
Study: 31188778
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), 9 individual sessions (weekly one session)
Study: 24286408
Drug: NPPV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPPV treatment group (NPPV group)
Study: 20924751
Drug: MDMA +
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA + THC (inhalation of 4, 6 and 6 mg, interval of 1.5 h)
Study: 17567341
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% with 75 microg fentanyl (1.5 ml)
Study: 17567341
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% with 1.5 ml saline
Study: 2913129
Drug: MC immunotherapy
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC immunotherapy
Study: 2913129
Drug: Placebo immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo immunotherapy
Study: 31540867
Drug: Semaglutide 1·0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 1·0 mg once weekly
Study: 31540867
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg once daily
Study: 29065390
Drug: Adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted treatment
Study: 23104320
Drug: Bupivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (10 cc of 0.5% bupivacaine)
Study: 23104320
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 cc of normal saline)
Study: 21325108
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g ethanol/kg body mass; n = 15)
Study: 21325108
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g ethanol/kg body mass) during progressive LBNP
Study: 19249634
Drug: Fampridine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fampridine (10 mg twice daily; n=229)
Study: 16600233
Drug: Polymorphisms of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms of peroxisome proliferator-activated receptor-gamma (Pro12Ala)
Study: 16600233
Drug: Polymorphisms of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms of peroxisome proliferator-activated receptor-coactivator-1 (Gly482Ser)
Study: 16600233
Drug: Body mass
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body mass index and reproductive hormones among various genotypic groups of PCOS
Study: 6775561
Drug: Naloxone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (15 mg, intravenously)
Study: 6775561
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (equivalent volume to naloxone)
Study: 6775561
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg, intravenously)
Study: 24429275
Drug: RPL554 (0.009
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPL554 (0.009 mg/kg)
Study: 24429275
Drug: RPL554 (0.018
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPL554 (0.018 mg/kg)
Study: 17284917
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with fluoride toothpaste or gel, and rinsing with a fluoride mouth rinse
Study: 14754644
Drug: 1% coal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% coal tar lotion (Exorex)
Study: 14754644
Drug: 5% conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% conventional coal tar lotion (Alphosyl)
Study: 10322856
Drug: Yizhi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yizhi capsule (YZC), 4 capsules each time, three times a day for two months
Study: 10322856
Drug: Yizhi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yizhi capsule (YZC)
Study: 10322856
Drug: Hydergine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine, 2 mg each time, three times a day for two months
Study: 3449477
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (6,000 rad)
Study: 3449477
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (5,000 rad)
Study: 3449477
Drug: Definitive radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiation therapy (6,500‐7,000 rad)
Study: 28696380
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (25 g of MuscleTech 100% Whey)
Study: 28696380
Drug: Rested control
Normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rested control trial (no exercise, no supplement)
Study: 24611590
Drug: Lokomat therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lokomat therapy combined with conventional therapy (twice a week Lokomat + three times 30 min conventional therapy)
Study: 24611590
Drug: Conventional assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional assisted overground therapy only (3.5 h a week)
Study: 8122957
Drug: Ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine hydrochloride (0.1 mg/kg)
Study: 2521863
Drug: CV 205-502
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CV 205-502 (0.01-0.05 mg initially, increased to 0.03-0.09 mg at 12 weeks)
Study: 9883
Drug: Hydrocortisone hemisucccinate
Normalized name: Hydrocortisone Hemisuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone hemisucccinate (150 mg/kg)
Study: 9883
Drug: Methyl prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl prednisolone sulfate (30 mg/kg)
Study: 9883
Drug: Prednisone sodium
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone sodium m sulfobenzoate (50 mg/kg)
Study: 9883
Drug: Prednisolone sodium
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone sodium m sulfobenzoate (35 mg/kg)
Study: 9883
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone phosphate (2 mg and 6 mg/kg)
Study: 25652389
Drug: Insulin deficiency
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin deficiency (fasting C-peptide ≤0.15 nmol/l)
Study: 25652389
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of IAA autoantibodies or baseline insulin use
Study: 15097308
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of elemental iron given twice weekly for four months
Study: 15097308
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of iron (not specified)
Study: 10762511
Drug: Immunocytochemistry using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocytochemistry using antibodies against phosphoepitopes
Study: 8614771
Drug: Stress Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress Management Treatment (SMT)
Study: 1466618
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) 0.1 mg/kg/day
Study: 6704272
Drug: Conventional i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional i.v. morphine (control)
Study: 24652598
Drug: Multi-professional treatment
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-professional treatment within a clinical pathway
Study: 23244640
Drug: Ecological momentary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecological momentary assessment (EMA) - self-monitoring negative thoughts five times daily for 2 weeks
Study: 16434656
Drug: Vardenafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (10 mg for 4 weeks, then maintained or titrated to 5 or 20 mg at weeks 4 and 8)
Study: 11075309
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (Citracal 250 mg + D)
Study: 11075309
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (Os-Cal 500 mg + D)
Study: 29867930
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy (MDT)
Study: 21417535
Drug: Immediate cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate cognitive-behavioral therapy (CBT)
Study: 21417535
Drug: Delayed cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed cognitive-behavioral therapy (CBT)
Study: 18332407
Drug: Chronic illness
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic illness management initiative involving joint formulation of comprehensive individual patient care plans
Study: 16520665
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate (SU11248) 50 mg after a high-fat, high-calorie meal
Study: 16520665
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib malate (SU11248) 50 mg after a 10-h fast
Study: 12920408
Drug: Other antipsychotics
Normalized name: Other antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antipsychotics and low doses of antiparkinsonians
Study: 10914361
Drug: Rate adaptive
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate adaptive atrial pacing therapy
Study: 10914361
Drug: No atrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No atrial pacing therapy
Study: 1319601
Drug: Smoked marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked marijuana and Oral THC
Study: 6478738
Drug: Diazepam 20
Normalized name: diazePAM 20 mg rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 20 mg + Methadone 100% of maintenance dose